HSA / FSA eligibility for GLP-1 medications
Use your pre-tax HSA or FSA dollars for Wegovy, Ozempic, Mounjaro, Zepbound and other GLP-1s — when they qualify. Per-drug rules, Letter of Medical Necessity templates, and the IRS Publication 502 language administrators care about.
The short answer
Usually yes. GLP-1s prescribed for a diagnosed condition — type 2 diabetes, or obesity/overweight — are generally HSA/FSA-eligible. For weight loss, most plan administrators require a Letter of Medical Necessity citing your diagnosis (per IRS Publication 502). Purely cosmetic weight loss is not eligible.
HSA vs FSA — the short version
HSA (Health Savings Account)
- • Requires enrollment in a High-Deductible Health Plan (HDHP).
- • Funds roll over year to year. You own the account.
- • 2026 limits: $4,400 individual / $8,750 family (subject to annual IRS update).
- • Triple tax advantage: pre-tax contributions, tax-free growth, tax-free withdrawals for qualified medical expenses.
FSA (Flexible Spending Account)
- • Employer-sponsored. No HDHP requirement.
- • "Use it or lose it" — most plans cap rollover at ~$640.
- • 2026 contribution cap: ~$3,300 (subject to annual IRS update).
- • Reimbursement requires substantiation: itemized receipt + sometimes a Letter of Medical Necessity.
What HSA / FSA actually covers for GLP-1s
The IRS treats a GLP-1 prescription as a qualified medical expense when it's prescribed for a specific diagnosed condition — type 2 diabetes, obesity (BMI ≥ 30, or ≥ 27 with comorbidity), or another FDA-approved indication. Off-label use for cosmetic weight loss does NOT qualify.
For diabetes drugs (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Byetta, Bydureon), the prescription itself documents the qualifying condition. A standard pharmacy receipt is normally sufficient for reimbursement.
For obesity drugs (Wegovy, Zepbound, Saxenda), most administrators require a Letter of Medical Necessity (LMN) from your prescribing physician. The LMN must state your diagnosis (typically the ICD-10 obesity code, e.g. E66.01) and confirm that the medication is medically necessary, not for general well-being or cosmetic purposes.
Medicare Part D — separate from HSA / FSA
Medicare Part D cannot cover medications prescribed for obesity / weight loss under the statutory exclusion at MMA 2003 §1860D-2(e)(2)(A). That carve-out applies to Medicare Part D plans, NOT to HSA or FSA accounts. Medicare beneficiaries with an HSA established before Medicare enrollment can still use HSA funds for an FDA-approved obesity GLP-1 with a valid Letter of Medical Necessity.
All 14 GLP-1 medications — at-a-glance
Typical administrator behaviour. Your specific plan may differ.
| Drug | Diabetes | Obesity | LMN required | Why |
|---|---|---|---|---|
| Bydureon | No | Bydureon is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Bydureon BCise | No | Bydureon BCise is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Byetta | No | Byetta is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Compounded liraglutide | Yes | Compounded liraglutide is not an FDA-approved finished drug. Eligibility for HSA / FSA reimbursement is case-by-case and many plans decline coverage even with a Letter of Medical Necessity. | ||
| Compounded semaglutide | Yes | Compounded semaglutide is not an FDA-approved finished drug, so eligibility is case-by-case. Even with a valid prescription and a Letter of Medical Necessity, many HSA / FSA administrators decline reimbursement for compounded products. | ||
| Compounded tirzepatide | Yes | Compounded tirzepatide is not an FDA-approved finished drug. Eligibility for HSA / FSA reimbursement is case-by-case and many plans decline coverage even with a Letter of Medical Necessity. | ||
| Mounjaro | No | Mounjaro is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. Off-label use for weight loss generally is NOT eligible. | ||
| Ozempic | No | Ozempic is FDA-approved for type 2 diabetes, so a standard prescription is normally sufficient for HSA / FSA reimbursement — no Letter of Medical Necessity required. Off-label weight-loss use generally is NOT eligible. | ||
| Rybelsus | No | Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Saxenda | Yes | Saxenda is FDA-approved only for chronic weight management. Most HSA / FSA administrators require a Letter of Medical Necessity documenting BMI ≥ 30, or ≥ 27 with a weight-related comorbidity. | ||
| Trulicity | No | Trulicity is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Victoza | No | Victoza is FDA-approved for type 2 diabetes. A standard prescription is normally sufficient for HSA / FSA reimbursement. | ||
| Wegovy | Yes | Wegovy is FDA-approved only for chronic weight management, so most HSA / FSA administrators require a Letter of Medical Necessity from your physician documenting a qualifying BMI (≥ 30, or ≥ 27 with a weight-related comorbidity). | ||
| Zepbound | Yes | Zepbound is FDA-approved only for chronic weight management and obstructive sleep apnea in adults with obesity. Most HSA / FSA administrators require a Letter of Medical Necessity documenting BMI ≥ 30, or ≥ 27 with a comorbidity. |
Sample Letter of Medical Necessity (LMN)
Generic, physician-completable template. Take this to your prescriber — they decide medical necessity and sign on their letterhead.
[Physician letterhead]
Date: ___________________
To: HSA / FSA Plan Administrator
Re: Letter of Medical Necessity for [patient name, DOB]
I am the treating physician for the above-named patient. Based on my clinical evaluation, the following medication is medically necessary for the treatment of a diagnosed disease, not for general well-being or cosmetic purposes:
- Medication: [Wegovy / Zepbound / Saxenda — brand & strength]
- NDC: [National Drug Code]
- Diagnosis (ICD-10): [E66.01 — morbid obesity / E66.9 — obesity, unspecified / E11.x — type 2 diabetes]
- Patient's BMI: [___ kg/m²]
- Relevant comorbidities: [hypertension, T2D, dyslipidemia, OSA]
This medication is FDA-approved and is being prescribed in accordance with its labeled indication. Duration of therapy is expected to be chronic / long-term.
Please reimburse the patient's out-of-pocket expense for this prescription as a qualified medical expense under IRS §213(d).
Signature: ___________________________
Name & credentials: ___________________________
NPI: ___________________________
Quick: find your BIN / PCN / Group
Already have your insurance card? Scan it in your browser — image never leaves your device — to extract the BIN, PCN, and Group fields you need to look up GLP-1 formulary coverage.
Where to start with a GLP-1 provider
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we compare providers, we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money